phase 1_completion
saveLife Science OHFC — stiripentol (Phase I Trial Completion)
community read0 votes
Therapy area: Genito Urinary System. Indication: Primary Hyperoxaluria, Primary Hyperoxaluria Type I, Primary Hyperoxaluria Type II, Renal Insufficiency
Data sources
globaldata
Found something off?
drug timeline · 7
- phase 1 completionSun Yat-sen University Hospital Seven — stiripentol (Phase I Trial Completion)Apr 30, 2026 · 162d ago
- approvalDIACOMIT (STIRIPENTOL) — FDA approvalApr 15, 2026 · 177d ago
- approvalDIACOMIT (STIRIPENTOL) — FDA approvalApr 15, 2026 · 177d ago
- approvalDIACOMIT (STIRIPENTOL) — FDA approvalJul 14, 2022 · 1548d ago
- approvalDIACOMIT (STIRIPENTOL) — FDA approvalJul 14, 2022 · 1548d ago
- approvalDIACOMIT (STIRIPENTOL) — FDA approvalAug 20, 2018 · 2972d ago
- approvalDIACOMIT (STIRIPENTOL) — FDA approvalAug 20, 2018 · 2972d ago
🐶 often sniffed alongside
top 8- drugDIACOMIT26 co-mentions · 8 sources
- tagApproval24 co-mentions · 6 sources
- companyBiocodex12 co-mentions · 6 sources
- tagSmall Molecule12 co-mentions · 6 sources
- tagOncology6 co-mentions · 1 sources
- companyLife Science OHFC1 co-mentions · 1 sources
- companySun Yat-sen University Hospital Seven1 co-mentions · 1 sources
- tagNephrology1 co-mentions · 1 sources
comments(0)
5-min edit window · permanent after that